VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | Optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia

Advances in the biological understanding of chronic myeloid leukemia (CML) and therapy with tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for patients with CML. At the 20th Congress of the European Hematology Association (EHA), Gianantonio Rosti, MD, of the University of Bologna, Bologna, Italy, considers the feasibility of first- and second-generation TKI treatment discontinuation in patients with CML, as well as how monitoring treatment responses and patient advocacy can impact outcomes.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter